A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype

Kaiyu Qian,Gang Wang,Lingao Ju,Jiyan Liu,Yongwen Luo,Yejinpeng Wang,Tianchen Peng,Fangjin Chen,Yi Zhang,Yu Xiao,Xinghuan Wang
DOI: https://doi.org/10.1038/s41388-020-01476-9
IF: 8.756
2020-09-25
Oncogene
Abstract:5–10% of total prostate cancer (PCa) cases are hereditary. Particularly, immune checkpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% of PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFR<sup>R831H</sup>. Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFR<sup>R831H</sup>-mutant tumours contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between the mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and PCa.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The problem this paper attempts to address is whether a novel germline EGFR variant (p.R831H) contributes to familial prostate cancer (PCa), particularly PCa with tandem duplicator phenotype (TDP) and biallelic CDK12 inactivation. ### Background - **Prostate Cancer (PCa)**: Approximately 449,800 new cases are diagnosed annually, with about 5-10% of cases being hereditary. - **TDP Phenotype**: Observed in 6.9% of PCa cases, which are sensitive to immune checkpoint inhibitor therapy. - **Genetic Susceptibility Genes**: Although some genes (e.g., BRCA2, PALB2, ATM) are known to be associated with familial PCa, they only explain a portion of PCa cases. ### Research Objectives - **Identify New Germline Variants**: Researchers identified two PCa patients in a Chinese family whose PCa phenotype co-segregated with a rare germline variant EGFR p.R831H. - **Functional Validation**: Experimentally validate whether the EGFR p.R831H variant leads to hyperactivation of the EGFR and AKT signaling pathways and explore its role in cell migration. - **Molecular Mechanism**: Analyze the relationship between the EGFR p.R831H variant and biallelic CDK12 inactivation, and whether this variant leads to the TDP phenotype. ### Key Findings - **EGFR p.R831H Variant**: Found in family members and showed selective copy number increase in tumor tissues, suggesting it may play a significant role in tumorigenesis. - **EGFR and AKT Signaling Pathways**: Cancer cells expressing EGFR p.R831H showed increased levels of EGFR and AKT phosphorylation. - **Cell Migration**: Cells with the EGFR p.R831H variant exhibited higher migration ability in migration assays, while the EGFR inhibitor Afatinib significantly reduced their migration ability. - **Biallelic CDK12 Inactivation**: Detected in the tumors of both patients, and this inactivation was associated with the TDP phenotype. - **Non-Invasive Diagnosis**: CDK12 mutations and copy number variations were detected in urine, suggesting potential applications in non-invasive diagnosis. ### Conclusion - **New Germline Variant**: The EGFR p.R831H variant may contribute to familial PCa, particularly PCa with TDP phenotype and biallelic CDK12 inactivation. - **Molecular Mechanism**: The EGFR p.R831H variant may promote tumorigenesis by enhancing the activity of the EGFR and AKT signaling pathways, leading to adaptive CDK12 inactivation. - **Clinical Significance**: These findings not only expand the list of genes associated with familial PCa but also provide new avenues for non-invasive diagnosis and monitoring, aiding in targeted therapy and the application of immune checkpoint inhibitors.